Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A limited sampling approach in bioequivalence studies

I Mahmood1, N Chamberlin, V Tammara

  • 1Division of Pharmaceutical Evaluation I, Office of Clinical Pharmacology and Biopharmaceutics, Food & Drug Administration, Rockville, MD 20852, USA.

Therapeutic Drug Monitoring
|August 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A bodyweight-dependent allometric exponent model for scaling clearance of clotting factor VIII and IX from infants to adults.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Occult hemopneumothorax following chest trauma does not need a chest tube.

European journal of trauma and emergency surgery : official publication of the European Trauma Society·2016
Same author

Predicting dosing advantages of factor VIIa variants with altered tissue factor-dependent and lipid-dependent activities.

Journal of thrombosis and haemostasis : JTH·2014
Same author

Designing first-in-human dose of coagulation factors: application of pharmacokinetic allometric scaling.

Haemophilia : the official journal of the World Federation of Hemophilia·2013
Same author

Allometric extrapolation of factors VII, VIII and IX clearance in children from adults.

Journal of thrombosis and haemostasis : JTH·2012
Same author

Allometric scaling of clearance in dogs.

Journal of veterinary pharmacology and therapeutics·2009

A limited sampling model (LSM) accurately predicts drug exposure (AUC and Cmax) for bioequivalence studies, reducing the need for extensive blood sampling. This method shows promise for simplifying pharmacokinetic assessments.

Area of Science:

  • Pharmacokinetics and Drug Development
  • Bioequivalence Studies
  • Statistical Modeling in Pharmacology

Background:

  • Traditional bioequivalence studies require extensive blood sampling to determine pharmacokinetic parameters like Area Under the Curve (AUC) and Maximum Plasma Concentration (Cmax).
  • Developing simplified methods for estimating these parameters can reduce patient burden and study costs.

Purpose of the Study:

  • To develop and validate a Limited Sampling Model (LSM) for predicting AUC and Cmax.
  • To compare the bioequivalence of two formulations for an antidepressant (Drug A) and an antiepileptic (Drug B) using predicted versus observed pharmacokinetic parameters.
  • To assess the feasibility of using LSMs to reduce blood sampling in bioequivalence assessments.

Main Methods:

  • Developed LSMs for Drug A (immediate-release antidepressant) and Drug B (controlled-release antiepileptic) using data from healthy subjects.

Related Experiment Videos

  • Employed simple regression analysis to correlate plasma drug concentrations at selected time points with AUC or Cmax.
  • Selected the linear regression with the highest correlation coefficient (r) as the optimal LSM for each drug.

    • Main Results:

    • The LSMs provided good estimates of AUC and Cmax for both drugs.
    • For Drug A, predicted AUC and Cmax fell within acceptable bioequivalence ranges, though predicted Cmax slightly exceeded the 90% confidence interval.
    • For Drug B, predicted AUC and Cmax also demonstrated good agreement with observed values, meeting bioequivalence criteria.

    Conclusions:

    • Limited Sampling Models can effectively estimate AUC and Cmax, supporting their use in bioequivalence studies.
    • This approach significantly reduces the need for extensive blood sampling, offering a more efficient alternative.
    • Further research is warranted to refine LSMs and expand their application across diverse drug formulations and patient populations.